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ABSTRACT 
 
The 26S proteasome has emerged as an attractive therapeutic target in the treatment of 
cancers. Proteasome inhibitors have been shown to selectively kill cancer cells. The FDA 
approval of bortezomib for the treatment of multiple myeloma and mantle cell lymphoma 
has clinically validated the 26S proteasome as a therapeutic target in oncology. Despite 
the acceptable therapeutic index, patients treated with this drug manifest several toxic 
side effects and moreover, the poor outcome of bortezomib treatment has been associated 
with acquired resistance to the drug. Currently, many efforts are made to develop new 
proteasome inhibitors that act through mechanisms distinct from that of bortezomib.  
 
In this theses we uncover a novel proteasome inhibitor of the 19S deubiquitinase activity, 
b-AP15. The inhibition of the proteasome function by this small molecule inhibitor is 
achieved through the inhibition of deubiquitinating enzymes UCHL5 and USP14 
resulting in the induction of poly-ubiquitinated proteins in cells. b-AP15 elicits anti-
tumor effects both in vitro and in vivo that is associated with the inhibition of proteasome 
function. In syngenic and xenograft mouse models, representing both solid and leukemic 
malignancies, b-AP15 exhibited potent antitumor activity causing tumor regression, 
reduced tumor growth and delayed tumor onset.  
 
b-AP15 elicits similar, but yet distinct, cellular response as bortezomib. b-AP15 induces 
rapid apoptotic response which is associated with strong increases of chaperone 
expression and strong induction of oxidative stress. Notably, these responses are stronger 
in cells exposed to b-AP15 than bortezomib. Similarly to bortezomib, b-AP15 induced 
ER stress being involved in the induction of apoptosis. b-AP15 is a reversible inhibitor 
of deubiquitinase activity and proteasome function. Despite being reversible inhibitor, b-
AP15 treated cells rapidly commit to apoptosis/cell death which we here report is due to 
rapid uptake and enrichment of the drug into cells.  
 
Bortezomib-mediated resistance has been associated with anti-apoptotic Bcl-2 
overexpression and induction of aggresome formation in cancer cells. Here we report 
that b-AP15 induced apoptosis is insensitive to the overexpression of Bcl-2 and that b-
AP15 blocks aggresome formation suggesting that bortezomib-mediated resistance could 
be overcome by b-AP15 treatment.  Furthermore, we found that b-AP15 is more toxic to 
cancer cells than immortalized normal cells with differences larger than those observed 
for bortezomib, suggesting more favorable therapeutic window of b-AP15 compared to 
bortezomib. The findings in this thesis strongly suggest that b-AP15 is a good candidate 
for clinical drug development.  
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INTRODUCTION 
 
CANCER AND CANCER TREATMENT 
Cancer consists of more than hundred different types of diseases that can affect any organ 
of the body. The different types of cancerous diseases share many features, like their 
origin from normal cells, limitless proliferation, loss of differentiation, and invasion of 
surrounding tissues leading to metastasis to other sites in the body. Cancer development 
is a multistep process involving a high number of mutations and other genetic and 
epigenetic alterations which drive the transformation of normal human cell to the 
malignant phenotype.  Moreover, cancer cells interact with the microenvironment (i.e. 
fibroblasts, vessels, macrophages, etc.) to fully display their phenotype [1]. 
Cancer is a leading cause of death worldwide. In 2008, 7.6 million people died from 
cancer which accounts for 13% of all deaths. Deaths from cancer are expected to rise to 
over 13.1 million in 2030 [2].   
Significant improvement of cancer survival has been reported in economically 
developed countries due to early diagnosis, universal access to health care and 
improvements in cancer therapy. The combined use of surgery, radiation therapy (RT) 
and chemotherapy accounts for most of the cured cases. RT accounts for 40% of cancer 
cure and utilization of RT in new cancer cases is increasing [3]. The common use of 
RT is in combination with surgery and/or chemotherapy. Most of the cytotoxic 
chemotherapeutic agents used to treat cancer today are DNA-damaging agents. The 
increasing knowledge in aberrant signaling pathways involved in cancer cell 
proliferation and survival has opened the door to new therapeutic strategies. At the 
present, there is an emphasis on designing new small molecules to repair these 
molecular defects in cancer cells in an attempt to eradicate the tumor. Some of these 
aberrations are appearing in a broad range of cancers making them attractive targets for 
drug development. However, combination therapy will still be essential for tumor 
eradication. The notion that cancer cells bear a high number of genetic aberrations, the 
blockade of a single pathway would not in many cases be enough to eradicate the tumor 
and furthermore, probable resistance mechanisms will defeat single agents. The huge 
challenge in the future is to identify patients who will respond to certain drugs which 
will be combined in a most effective way.  
 
 
THE UBIQUITIN PROTEASOME PATHWAY IN CANCER  
 
Background  
The degradation of cellular proteins is a highly complex and tightly regulated process 
that regulates many processes important for cell growth and survival. The concept of 
protein turnover is almost 60 years old. Before the discovery of the ubiquitin proteasome 
pathway (UPP), 20 years ago, it was known that some intracellular protein degradation 
occurred via the lysosome, in a process termed autophagy. This provided a mechanism 
to explain how intracellular proteins existed in a dynamic balance between synthesis and 
degradation but it did not explain all aspects of the regulation of intracellular proteins. 
With the discovery of the ubiquitin system in the late 1970s and early 1980s a new era in 
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the protein degradation field occurred [4]. Aaron Ciechanover, Avram Hershko, and 
Irwin Rose were awarded the Nobel Prize in Chemistry in 2004 for the discovery of 
ubiquitin-mediated protein degradation. 
Estimates suggest that more than 80% of cellular proteins are degraded by the UPP, 
indicating the importance of this pathway in the regulation of many of the cellular 
processes [5]. The UPP is implicated in the degradation of abnormal and damaged 
proteins, of cell cycle regulators, of proteins encoded by oncogenes and tumor suppressor 
genes, in the processing of antigens, and the activation or degradation of transcription 
factors [6, 7].  
As such this pathways has been implicated in the pathogenesis of many human diseases, 
including neurodegenerative disorders, viral diseases and cancer [8]. In this thesis, the 
main focus will be on UPP and its role in cancer. 
 
Overview of the UPP 
The proteasome has been highly conserved during eukaryotic evolution, with simpler 
forms found even in archaebacteria and eubacteria [9, 10]. The proteasome is a large 
multisubunit protease (2.5 MDa) that is found in the cytosol and in the nucleus of 
eukaryotic cells [11]. It is an ATP-dependent protease [12, 13]. This large structure 
consists of approximately 50 different subunits and is arranged into two subcomplexes: 
catalytic 20S core particle (CP) capped by the 19S regulatory particle (RP), which 
together form the 26S proteasome. The CP is a barrel-shaped structure of ∼730 kDa 
consisting of four heptameric rings, whereas the 19S RP is a ∼930 kDa complex 
constituting at least 19 different subunits. The 19S RP binds to one or both ends of the 
CP to form an enzymatically active proteasome. The most abundant proteasome species 
at least in yeast cells is composed of one CP capped by two RP. It is still unclear whether 
there are functional differences between different species, although the high degree of 
conservation does suggest a common function [7, 14, 15].  
Proteins destined to be degraded by the proteasome are initially tagged by a covalently 
linked poly-ubiquitin chain that is recognized as a degradation signal by the 19S RP. 
Once recognized, the ubiquitin chain is removed and the protein is unwound in an ATP 
dependent manner and fed into the center of the 20S complex, where it is degraded into 
small peptides (Figure 1) [16].   
The rates of protein synthesis, folding and degradation in cells have been estimated in 
mouse L929 cells. A typical protein was defined to be 450 residues, leading to estimation 
that the protein content of these cells was 2.6 × 109 proteins per cell. Proteasomes are fed 
with both slowly degraded proteins (SDPs) and rapidly degraded proteins (RDPs). 
Approximately 30% of newly synthesized proteins in mammalian cells are degraded with 
a half-life of <10 min. In actively dividing cells (1 day doubling time), RDPs provide 1.3 
× 106 substrates per min per cell. Slowly degraded proteins have a half-life average of ~2 
days. The contribution of SDPs to proteasomal degradation amounts to ~5 × 105 
substrates per min per cell. The total amount of proteasomal substrates is therefore ~2 × 
106 proteins degraded per min per cell, generating ~108 oligopeptides per min per cell 
[17-19].  
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Figure 1. Ubiquitin-dependent protein degradation. 
 
Ubiquitination 
Ubiquitination is a multi-step process leading to labeling of a substrate for degradation 
by the proteasome. A key protein in this process is ubiquitin (Ub), which is a highly 
conserved small (8.5kDa) regulatory protein consisting of 76 amino acids. 
Ubiquitination is dependent on three distinct enzymes, Ub-activating (E1), Ub-
conjugating (E2) and Ub-ligating (E3). These enzymes activate free ubiquitin and 
catalyze its covalent addition to substrate protein.  
Ubiquitin is first activated by the E1 enzyme in the presence of ATP, forming a high-
energy thiolester bond between the carboxy-terminal glycine residue of ubiquitin and the 
active site cysteine of E1. In mammalian organisms, a single, functional E1 enzyme has 
been found. Once activated, the ubiquitin is transferred from E1 to a cysteine residue of 
one of the 30 to 40 ubiquitin carrier proteins or E2s, thereby generating yet another 
thiolester intermediate. Specific E2s function in the degradation of various types of 
substrates by conjugating with various E3 ligases. E3 ligases bind target substrates and 
attach ubiquitin from E2 to a lysine residue of a substrate, resulting in the formation of 
ubiquitin chain covalently linked to the substrate (Figure 2). There are >1000 different 
types of E3 ligases in cells making them the main specificity factor in the UPP [20-22]. 
There are three different classes of ubiquitination: i) mono-ubiquitination: a single 
ubiquitin is bound to the substrate, ii) multiubiquitination or poly-monoubiquitination: 
several single ubiquitin moieties are bound to the substrate, iii) poly-ubiquitination: 
substrates are tagged with poly-ubiquitin chains. Different cellular processes are 
regulated depending on the type of the modification of the substrate [23, 24]. For 
example, mono-ubiquitination has been shown to control numerous cellular processes 
such as receptor transport, viral budding and DNA repair [25]. Most substrates require 
poly-ubiquitination to be delivered to the proteasome. The attachment of a chain of four 
or more ubiquitin molecules to a protein is required for efficient degradation [26, 27]. 
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There are several types of ubiquitin linkages depending on the lysine residue involved 
in the formation of the poly-ubiquitin chain involving one or more of the seven lysine 
residues (Lys6, Lys11, Lys27, Lys29, Lys33, Lys48 and Lys63) of the ubiquitin moiety. 
Ubiquitin chains can vary in their length and linkage type. Depending on the type of 
poly-ubiquitin chain, modified proteins are destined to different cellular fates. The best 
known is the Lys48-linked poly-ubiquitin chain being involved in the proteasomal 
degradation of proteins [6], whereas the Lys63-linked poly-ubiquitin chain has been 
shown to be involved in DNA repair, DNA replication and signal transduction processes 
[23]. This has been the picture for many years but the recent studies have added another 
level of complexity. Linkages other than Lys48 appear to be involved in targeting 
proteins to the proteasome for degradation with poly-ubiquitin chains linked through 
Lys6, Lys11, Lys27, Lys29, or Lys33 [28]. Even Lys63 chains, which have been 
assumed to provide a signaling rather than degradation function, can target for 
proteasome degradation [29].  
 
 
 
Figure 2.  The ubiquitination system 
 
The process of ubiquitination can be reversed by specific deubiquitinating enzymes 
(DUBs), thereby controlling the balance between E3 ligases and DUBs. The balance 
of chain-extending and chain-trimming activities is required for proper proteasome 
function. Through opposing activities of HECT ubiquitin ligase 5 (Hul5) and the 
proteasome DUB, Ubp6/USP14, ubiquitin chains on bound substrates are extensively 
remodeled by the 26S proteasome [30].  
Most of the proteasomal substrates are recognized by poly-ubiquitin chains [6]. In 
contrast, the enzyme ornithine decarboxylase (ODC) is recognized by the proteasome 
through a mechanism independent of ubiquitination. The enzyme plays a key role in 
the polyamine biosynthesis. Instead of binding poly-ubiquitin chains, ODC degradation 
by the proteasome involves binding of polyamine-induced protein (antizyme) [31, 32].  
 
19S regulatory particle 
The ubiquitinated substrate is recognized by the 19S RP followed by the removal of the 
ubiquitin chain by the deubiqitinating ezymes (DUBs), unfolding and translocation of 
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the unfolded substrate protein to the 20S CP for degradation. The 19S RP consists of at 
least 19 different subunits with molecular masses ranging from 10 to 110 kDa and can 
be divided into two subcomplexes: the lid and the base [26].  
The lid of the 19S RP is composed of nine non-ATPase subunits Rpn3, Rpn5–Rpn9, 
Rpn11, Rpn12, and Rpn15 (Figure 3). Overall, Rpn3, Rpn7, Rpn6, Rpn5 and Rpn9 form 
the fingers of the hand-shaped lid structure.  Rpn11/POH1, the only essential DUB of the 
proteasome, lies in the palm of the hand and makes extensive contacts with Rpn8, Rpn9 
and Rpn5 [26, 33-35].  
The base is composed of ten subunits and six are related AAA+ ATPase (Rpt1-Rpt6) that 
form a hetero-hexameric ring with the specific order of Rpt1-Rpt2-Rpt6-Rpt3-Rpt4-Rpt5 
[36]. A loop, called Ar-Φ (aromatic-aliphatic) loop, protrudes from every subunit into 
the center of the ATPase ring [37]. The AAA+ domains of the ATPase subunits are 
responsible for the contact with the folded protein substrate through the loops. The loops 
undergo conformational changes by utilizing the energy from ATP hydrolysis resulting 
in the production of pulling pulses that unravel the tertiary and secondary structures of 
protein substrates. The unfolded substrate is then translocated through a narrow central 
pore into the 20S CP peptidase chamber for degradation [38-40]. The ATPase ring plays 
an important role in the opening of the gated channel for substrate degradation, primarily 
involving two of the six ATPases (Rpt2 and Rpt5) [41, 42].  
Rpn1 and Rpn2 are the largest subunits of the proteasome which are associated with the 
ATPase ring within the base (Figure 3). Rpn1 and Rpn2 are important subunits regarding 
ubiquitin chain dynamics by binding enzymes that disassemble or extend ubiquitin 
chains. For example, DUB Ubp6/USP14 binds proteasomes via Rpn1 and the ubiquitin 
ligase Hul5 binds proteasomes through Rpn2 [30, 43, 44].  
 
 
 
 
Figure 3. Schematic diagram of the 26S proteasome complex. Yeast nomenclature for the different subunits. 
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Most substrates dock at the proteasome via specific ubiquitin receptors. There are five 
ubiquitin receptors known to associate with the proteasome: two 19S RP base subunits, 
Rpn10 and Rpn13, and three extrinsic ubiquitin receptors Rad23, Dsk2, and Ddi1. 
Yeast cells with mutations in all five ubiquitin receptors remain viable, indicating that 
other ubiquitin receptors may exist [45-48]. Rpn10 was the first receptor found to bind 
the poly-ubiquitin chain [45]. It contains two C-terminal ubiquitin-interacting motif 
(UIM) for ubiquitin binding. These two domains cooperate when there is more than one 
ubiquitin present in a conjugate [46, 49]. The other integral ubiquitin receptor, Rpn13, 
binds ubiquitin via pleckstrin-like receptor for the ubiquitin (Pru) domain. Rpn13 bind 
Lys48-linked di-ubiquitin with high affinity. Rpn13 serves also as a receptor for 
Uch37/UCHL5 deubiquitinating enzyme, linking chain recognition and disassembly 
together [48]. The extrinsic ubiquitin receptors (Rad23, Dsk2, and Ddi1) contain 
ubiquitin-like (UBL) domain which bind to the 19S RP subunits Rpn1, Rpn10 and Rpn13 
and ubiquitin-associated (UBA) domain binding poly-ubiquitinated substrates [47]. 
There is a theory that conjugates arrive at the proteasome on these extrinsic receptors and 
are handed off to intrinsic receptors, Rpn10 and Rpn13. The UBA domains in these 
ubiquitin receptors may have preferential affinities for different ubiquitin linkages and 
different chain lengths [50, 51]. 
The lid complex is connected to the base complex by interactions between Rpn12  and 
Rpn2, and between Rpn11 and Rpn1. Rpn10 might be involved in stabilizing these 
interactions [33]. The major activity of the lid and the base is proposed to be 
deubiquitination [34, 35, 52, 53]. 
 
20S core particle 
The basic understanding of the structure of the 20S CP came from the studies of the 
archaeon Thermoplasma acidophilum. The prokaryotic 20S CP consist of homo-
oligomers of the same α and β subunits, i.e., the αββα structure. The eukaryotic 20S CP 
is a cylinder-shaped multimeric complex which is formed by axial stacking of four 
heteroheptameric rings composed of two outer α-rings and two inner β-rings. Each ring 
contains seven homologous members resulting in the general structure of the complex 
α1–7β1–7β1–7α1–7 [54, 55]. 
In yeast and in higher eukaryotes the 20S CP contains three proteolytically active sites 
β1, β2 and β5, while the other β-subunits, β3, β4, β6 and β7 are catalytically inactive. 
The catalytically active β-subunits contain catalytically active threonine residues at their 
N-termini. The β1, β2, and β5 subunits are associated with caspase-like/PGPH 
(peptidylglutamyl-peptide hydrolyzing), trypsin-like, and chymotrypsin-like activities, 
respectively, which confer the ability to cleave peptide bonds at the C-terminal side of 
acidic, basic, and hydrophobic amino-acid residues, respectively. The active sites face 
the interior space of the 20S CP [56, 57]. The three peptidase activities of the 20S 
proteasome can be easily probed with specific fluorogenic peptides and are very often 
monitored as a measure of proteasomal activity in vitro. Many of the proteasome 
inhibitors have these activities as targets [58].  
While β rings possess proteolytically active sites, the outer α rings provide attachment 
sites for the 19 S RP and control the access of substrates to the catalytic chamber by 
serving as a gated channel. The channel of the α-ring is very narrow (∼13 Å in diameter) 
and is mainly composed of α2, α3 and α4 subunits. Thus, substrates destined to be 
degraded must pass this narrow channel to access the active sites of catalytic enzymes at 
the center of the α-ring. Substrate proteins are degraded into oligopeptides ranging in 
length from 3 to 15 amino-acid residues. The resulting peptide products are hydrolyzed 
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to amino acids by different peptidases [54, 59-61]. If not hydrolyzed to amino acids, 
oligopeptides can be used by histocompatibility complex (MHC) class I molecules for 
presenting intracellular/endogenous antigens to the immune system [62]. 
 
Deubiquitinating enzymes of the 26S proteasome 
Why do proteasomes deubiquitinate substrates? Substrate deubiquitination is required 
for efficient proteolysis. Access to the opened channel into the 20S CP is sterically 
impeded by covalently linked poly-ubiquitin chains, thus cleavage and removal of the 
ubiquitin chain is required for substrate translocation and degradation [34, 35]. 
Deubiquitinating enzymes are also responsible for the recycling of free ubiquitin in the 
cell. This process is vital for keeping sufficient levels of free ubiquitin that can be used 
for chain assembly. If not cleaved from the substrate, some ubiquitin can be translocated 
into the CP along with the substrate and be degraded [63]. DUB activity is also required 
for clearing substrate-free poly-ubiquitin chains stuck to the proteasome so that new 
poly-ubiquitinated substrates can bind to these sites. Yet, another function of 
deubiquitinating enzymes is to rescue poorly ubiquitinated substrates from degradation 
by trimming the poly-ubiquitin chain from the distal end [64].  
There are at least 98 DUBs encoded by the human genome which are divided into six 
classes: ubiquitin-specific proteases (USPs), ubiquitin carboxy-terminal hydrolases 
(UCHs), ovarian-tumor proteases (OTUs), Machado–Joseph disease protein domain 
proteases, JAMM/MPN domain-associated metallopeptidases (JAMMs) and monocyte 
chemotactic protein-induced protein (MCPIP) [65]. 
Three DUBs are associated with the proteasome: Rpn11/POH1, Ubp6/USP14 and 
Uch37/UCHL5 (yeast/human nomenclature). Rpn11/POH1 is a metalloprotease which 
belongs to the JAMM domain family and is an integral part of the lid of the 19S RP. 
Ubp6/USP14 and Uch37/UCHL5 are cysteine proteases and members of the ubiquitin 
C-terminal hydrolases (UCH) and ubiquitin specific proteases (USP) families, 
respectively. They are physically associated with the base complex of the 19S RP. 
Deubiquitination is carried out by the hydrolysis of the isopeptide bond in ubiquitin–
protein conjugates [34, 35, 43, 52, 53].  
 
Rpn11/POH1 
Rpn11/POH1 is essential for viability in yeast and cancer cells [66, 67]. In addition to 
its function as a DUB, Rpn11/POH1 is essential for 26S proteasome structure and 
activity. Knock-down experiments of Rpn11/POH1 disrupted the assembly of the 26S 
proteasome leading to the inhibition of the activity of the proteasome [68]. 
Rpn11/POH1 contains a JAMM/MPN+ motif sequence containing two histidine residues 
and an aspartic residue coordinating a zinc ion, which is important for the proteolytic 
activity of this deubiquitinating enzyme [69, 70]. Indeed, JAMM/MPN+ motif was 
required for cell viability of cancer cells mentioned before [67]. Hydrolysis of ATP is 
required for Rpn11/POH1-dependent deubiquitination, suggesting that 
deubiquitination is coupled to protein unfolding by the ATPases. Rpn11/POH1 is 
localized directly above the entrance of the ATPase ring by being cross-linked to the N-
terminal coiled-coil domain of Rpt3. This position is ideal for removal of ubiquitin from 
substrates immediately before the translocation of the substrate into the CP. The activity 
of Rpn11/POH1 is thought to be delayed until the proteasome is committed to degrade 
the substrate [34, 35, 71]. Rpn11/POH1-mediated deubiquitination promotes substrate 
degradation by cutting at the base of the chain resulting in the release of entire poly-
ubiquitin chain. To allow cleavage without disengaging from the receptor, an ubiquitin 
chain must be long enough to span the distance between receptor and DUB. At least four 
ubiquitin moieties are necessary to span the distance between receptors Rpn10 or Rpn13 
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and Rpn11/POH1 [26, 34, 35]. Lys63-linked poly-ubiquitin chains are the preferable 
substrates for Rpn11/POH1 [72]. 
 
Ubp6/USP14 
Unlike Rpn11/POH1, Saccharomyces cerevisiae orthologue of USP14, Ubp6, is 
nonessential for cell viability [73]. Knock-down of Ubp6/USP14 had no detectable effect 
on proteasome structure indicating that it is not an integral subunit of the proteasome 
[64]. The full-length human Ubp6/USP14 contains 494 amino acids, with a 9-kDa UBL 
domain at its N-terminus followed by a 45-kDa catalytic domain. The catalytic domain 
of Ubp6/USP14 resembles an extended right hand comprised of three domains: Fingers, 
Palm, and Thumb. The binding pocket of ubiquitin is located between the Fingers and 
the Palm–Thumb scaffold and contains two surface loops (BL1 and BL2) that are located 
above, which block the binding of ubiquitin. Thus, the blockade of the ubiquitin binding 
groove by loops BL2 and BL1 must be removed in order for Ubp6/USP14 to catalyze 
deubiquitination [53, 74]. Ubp6/USP14 has been shown to reversibly associate with the 
Rpn1 subunit of the base in the 19S RP via its UBL domain. It has been proposed that 
the binding of Ubp6/USP14 to the base of the 19S RP induce conformational changes in 
the two loops to make the active site for ubiquitin accessible [74]. Association with the 
proteasome increases Ubp6/USP14 catalytic activity several hundredfold. Ubp6/USP14 
can be dissociated from the proteasome under high-salt conditions [43, 64].  
Ubp6/USP14 is located at the largest distance from the entrance of the pore of all the 
ubiquitin-interacting subunits in the RP, which may allow it to clip extended or 
unnecessary ubiquitin chains from substrates [26]. Lys48-linked poly-ubiquitin chains 
are the preferable substrates for Ubp6/USP14 and are cleaved from their distal end or 
within the chain [74, 75].  
Ubp6/USP14 has several functions at the proteasome, which are dependent on the 
deubiquitinating activity of this enzyme but also non-catalytic effects of Ubp6/USP14 
have been reported. Ubp6/USP14 is important for ubiquitin recycling. Loss of ubiquitin 
pools severely impair the ability of the proteasome to clear unwanted proteins from the 
cell, being dependent on ubiquitin for tagging, and result in protein accumulation. 
Depletion of free ubiquitin up-regulates proteasome bound Ubp6/USP14 and loss of 
Ubp6/USP14 results in increased degradation of ubiquitin and decreased levels of 
monomeric ubiquitin [75-77]. 
Ubp6/USP14 was shown to inhibit proteasome activity independently of its 
deubiquitinating function by delaying the breakdown of proteins by the proteasome. It is 
suggested that Ubp6/USP14 prevents deubiquitination of the substrate by Rpn11/POH1. 
This allows the substrate to be docked at the proteasome for a longer time, thus resulting 
in more extensive trimming of ubiquitin chains, which reduces substrate binding affinity 
to the proteasome and favors its release back to the cytosol [75, 78]. Conversely, the 
small molecule USP14 inhibitor IU1 was shown to reduce chain trimming and stimulate 
proteasome degradation, indicating the ability of USP14 to inhibit the proteasome 
through its deubiquitinating activity [79]. Ubp6/USP14 is also involved in the regulation 
of gate opening of the 20S core particle.  Binding of ubiquitin conjugates to the 26S 
proteasome increases peptide hydrolysis by increasing 20S gate opening. Ubiquitin 
conjugates interact with Ubp6/USP14 and in this way stimulate gate opening, enabling 
the substrate to be degraded [80]. It has been found that most of the cellular Ubp6/USP14 
is not associated with the proteasome, indicating that it may be involved in other cellular 
processes [64]. 
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Uch37/UCHL5 
The Uch37/UCHL5 deubiquitinase is well conserved from fungi to humans [81]. An 
orthologue of human Uch37 has not been found in Saccharomyces cerevisiae. However, 
the orthologue in Saccharomyces pombe, Uch2, is nonessential for viability [82]. When 
identified, Uch37/UCHL5 was first shown to be a stoichiometric component of the 26S 
proteasome [83], but has later been shown, in several reports, to reversibly associate with 
the proteasome [81, 84-86]. In contrast to Rpn11/POH1, Uch37/UCHL5 is not important 
for the activity or the structure of the 26S proteasome. Uch37/UCHL5 consists of 329 
amino acids (molecular mass 37K) and has two functional domains, a catalytic domain 
(UCH-domain) and a C-terminal domain. The deubiquitinase activity of the 
Uch37/UCHL5 is enhanced when bound to 26S proteasome [64] via the Rpn13/Admr1 
receptor in the 19S RP base complex. The N-terminal Pru domain of Rpn13/Admr1 binds 
to the proteasome (Rpn2 subunit of the 19S RP), whereas it’s C-terminal domain binds 
to the C-terminus of Uch37/UCLH5. The UCH-domain contains an active-site crossover 
loop, and unless displaced, blocks substrate entry. This auto-inhibitory function is 
reversed by binding of Uch37/UCHL5 to Rpn13/Admr1, resulting in the release of the 
loop and activation of the enzyme. Incorporation of the Uch37/UCHL5 to 26S 
proteasome is required for efficient deubiquitinating activity [81, 84, 86]. Similarly to 
Ubp6/USP14, Uch37/UCHL5 removes ubiquitin from the distal end of the chain. Thus, 
it does not remove chains en as a single unit but progressively shortens them. While 
Ubp6/USP14 is able to release di- and tri-ubiquitin from substrates, Uch37/UCHL5 
releases only mono-ubiquitin from chains [52, 75]. Uch37/UCHL5 cleaves both Lys48- 
and Lys63-linked poly-ubiquitin chains [87]. It is believed that Uch37/UCHL5 
suppresses protein degradation by shortening the chain of inappropriately or poorly 
modified substrates [52, 64]. In contrast, a recent study has suggested that 
Uch37/UCHL5 promotes the degradation of specific proteasome substrates, nitric oxide 
synthase and IκB-α [88]. In conclusion, Uch37/UCHL5 can suppress the degradation 
of some substrates while promoting the degradation of others. 
 
Cooperative functions of proteasomal DUBs 
It is unclear why so many activities are required for deubiquitination at the proteasome 
and how they are related to one another, but there are some suggestions that 
Rpn11/POH1, Ubp6/USP14, and Uch37/UCHL5 cooperate to provide effective 
processing of ubiquitin chains. As mentioned above, the substrate must be committed to 
degradation before the poly-ubiquitin chain is removed by Rpn11/POH1. Both 
Usp6/USP14 and Uch37/UCHL5 trim poly-ubiquitin chains from the distal end before 
the poly-ubiquitin chain is removed by Rpn11/POH1 [49]. It has been proposed that 
Ubp6/USP14 and Uch37/UCHL5 complement the function of Rpn11/POH1. 
Rpn11/POH1 cleaves the entire ubiquitin chains resulting in the release of the substrate 
to be degraded by the proteasome. Substrate-free poly-ubiquitin chains remain associated 
with the proteasome and must be removed so that new substrate-bound poly-ubiquitin 
chains can bind. Ubp6/USP14 and Uch37/UCHL5 accomplish this function by 
hydrolyzing these poly-ubiquitin chains. The exact difference in catalytic function 
between Ubp6/USP14 and Uch37/UCHL5 are not clear, but the activities appear to 
operate in similar ways. Double knockdown of Ubp6/USP14 and Uch37/UCHL5 results 
in inhibition of cell growth, decreased protein degradation, and accumulation of poly-
ubiquitinated proteins, a cellular phenotype similar to that observed after knock-down of 
Rpn11/POH1 [68]. RNAi-mediated down-regulation of either DUB alone creates a 
complete opposite phenotype where the cell growth was not affected and reduced levels 
of poly-ubiquitinated proteins was observed, indicating that each enzyme could 
compensate for loss of function of the other [64].  
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The role of proteasomal deubiquitinases in cancer 
As mentioned previously, the important role of Rpn11/POH1 for cancer cell viability 
makes it an obvious target for cancer therapy [66, 67]. Over-expression of Rpn11/POH1 
has been shown to promote resistance to several chemotherapeutic drug being used in 
the clinic today, e.g. vinblastine, doxorubicin, cisplatin. Rpn11/POH1-induced drug 
resistance is suggested to be mediated through AP-1 transcription factors [89]. 
Rpn11/POH1 is also involved in the regulation of the ErbB2 receptor, which has been 
associated with poor prognosis and malignancy of breast cancer when highly expressed. 
It is believed that Rpn11/POH1 deubiquitinates ErbB2 and instead of destruction, ErbB2 
is rescued from proteasomal degradation [90]. Thus, inhibiting Rpn11/POH1 would be 
beneficial for breast cancer patients with ErbB2 positive tumors.  
To date, there are only a few studies on the potential role of Ubp6/USP14 in cancer. Thus, 
the understanding of the role of Ubp6/USP14 in cancer biology is very limited. Levels 
of Ubp6/USP14 were first found to be elevated in leukemic and colon cancer cell lines 
[91, 92]. The levels of Ubp6/USP14 have also been associated with overall survival rate 
in colorectal cancer patients, being worse in patients with high expression of the enzyme 
than in those with low expression levels. This high expression correlated also with 
histological stage, lymph node and liver metastases [93]. Recently, a study on lung 
adenocarcinoma revealed a high expression of Ubp6/USP14 in both cell lines and tumor 
tissue. The overexpression of Ubp6/USP14 promoted cell proliferation by induction of 
β-catenin and was significantly correlated with overall survival of lung adenocarcinoma 
patients [94].  
There are several studies on Uch37/UCHL5 and its role in oncogenesis. Deregulation in 
the transforming growth factor-β (TGF-β) signaling cascade is a common occurrence 
in human cancers. In the late stage cancers, TGF-β switches from being a tumor 
suppressor to a tumor promoter. Cancer cells use TGF-β to initiate cell migration and 
metastases [95]. Uch37/UCHL5 has been shown to interact with Smad7 involved in 
TGF-β signaling. Thus, up-regulation of Uch37/UCHL5 plays an important role in the 
late stage of tumor development.  Smad7 has been shown to function as an adaptor that 
recruits the Smurf E3 ubiquitin ligase to the TGF-β receptor complex to promote its 
ubiquitination and proteasomal degradation. Uch37/UCHL5 interaction leads to 
deubiquitination of the TGF-β receptor thereby rescuing it from proteasomal degradation 
and promotion of TGF-β signaling [96]. Taken together aberrant Uch37/UCHL5 levels 
play important role in cell migration and metastases which has been shown by Cutts and 
colleagues [97].   
Another way of Uch37/UCHL5 to promote cell survival is by altering the expression of 
apoptosis mediators. Silencing of Uch37/UCHL5 in lung adenocarcinoma epithelial cell 
line A549 was shown to induce apoptosis through activation of caspase-3 and caspase-
9. In these cells anti-apoptotic Bcl-2 protein was down-regulated while pro-apoptotic Bax 
protein was up-regulated. Conversely, the overexpression of Uch37/UCHL5 had the 
opposite effect [98]. 
Uch37/UCHL5 has been shown to be up-regulated in several carcinoma tissues 
compared to the adjacent normal tissues [99-101]. In esophageal squamous cell 
carcinoma the expression of Uch37/UCHL5 was closely related with lymph node 
metastases and TNM (Classification of Malignant Tumors) stage and was also 
significantly correlated with patients’ overall survival and disease free survival [100]. 
Uch37/UCHL5 was also found to be highly expressed in hepatocellular carcinoma 
(HCC) tissues. In HCC cell lines, Uch37/UCHL5 promoted cell migration and invasion 
by deubiquitinating PRP19, an essential RNA splicing factor [101].   
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The ubiquitin proteasome pathway in cell physiology 
 
The Role of UPP in cell proliferation and cell death 
Many important targets of the 26S proteasome that have been identified are important 
players in cell proliferation and cell death including cyclins [102-104], tumor suppressor 
protein p53 [105], pro-apoptotic protein Bax [106], cyclin dependent kinase inhibitor 
(CKI) p27 [107] and the nuclear factor kappaB (NF-κB) inhibitor, IκB [108]. The 
degradation of specific cellular proteins by the 26S proteasome determines whether a cell 
proliferates or dies [109]. The UPP is involved in the regulation of many of the apoptosis 
pathway molecules and generally contributes to apoptosis resistance in cancer cells. 
Thus, the induction of apoptosis by proteasome inhibitors is out of key importance [110]. 
The UPP regulates levels of both pro- and anti-apoptotic proteins and inhibition of the 
proteasome activity up-regulates pro-apoptotic factors such as p53 and Bax while 
reducing levels of anti-apoptotic proteins such as Bcl-2 [111]. The proteasome activity 
has been shown to be elevated in many kinds of cancer contributing to tumorigenesis by 
providing cancer cells with anti-apoptotic protection and uncontrolled cell division [106, 
112-114].  
 
Cell cycle  
In normal cells, the cell cycle is tightly controlled by a number of signaling pathways 
leading to cell growth, DNA replication and cell division. The UPP is involved in the 
degradation of many of the proteins that regulate the cell cycle leading to cell growth. 
Uncontrolled cell proliferation is a hallmark of cancer [1]. There are three key classes of 
regulatory molecules involved in the control of the cell cycle: cyclins, cyclin-dependent 
kinases (CDKs) and cyclin-dependent kinase inhibitors (CKIs), which require 
programmed and periodic expression, and degradation for cell cycle progression. The 
most important mechanism of cell cycle control is the activation of CDKs, which are 
regulated by the ubiquitin-dependent proteolysis of cyclins (D, E, A, B) and CKIs (p21 
and p27) [115]. There are several ubiquitin ligases involved in the regulation of cell cycle, 
which are responsible for the ubiquitination of the CKIs or cyclins and their degradation 
by the 26S proteasome [116]. Their primary targets are tumor suppressor proteins p53, 
p21 and p27 [117-119]. Cyclin D and E have been shown to be up-regulated in different 
malignancies while CKIs (p21 and p27) are suppressed in several cancer types to 
promote tumor progression [120-122]. Inhibition of proteasome function leads to 
accumulation of p27 and p21 followed by the induction of cell cycle arrest and apoptosis 
[109, 123, 124].  
 
p53 
The tumor suppressor p53 is an important regulator of apoptosis. p53 levels are tightly 
regulated through interaction with its negative regulator Mdm-2, which is an E3 ubiquitin 
ligase. Under normal conditions it is held inactivated and ubiquitinated by Mdm2 leading 
to degradation by the 26S proteasome [105, 119, 125]. In response to DNA damage, 
hypoxia and inappropriate oncogene signaling, wild-type p53 is induced resulting in 
activation of transcription of genes that induce growth arrest and apoptosis [126]. 
Mutations in the p53 gene are common in many types of cancer leading to tumor 
progression [127]. Induction of p53-dependent apoptosis by proteasome inhibitors has 
been demonstrated in different malignancies [128-130]. In contrast, proteasome 
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inhibitors are also able to induce apoptosis independently of the p53 status in cancer cells 
[131, 132]. 
 
NF-κB 
Nuclear factor kappaB (NF-κB) is a transcription factor that is also involved in the 
regulation of apoptosis pathways and its activation is regulated by the UPP. When 
activated, NF-κB suppresses apoptosis by initiating the transcription of genes encoding 
anti-apoptotic proteins such as Bcl-2 and IAPs (inhibitors of apoptosis) [133-135]. Under 
normal circumstances, NF-κB is sequestered in the cytoplasm through association with 
its endogenous inhibitor IκB [136]. Upon stimulation, IκB is phosphorylated, poly-
ubiquitinated by an E3 ubiquitin ligase and degraded by the 26S proteasome, resulting in 
the translocation of NF-κB into the nucleus and thereby initiating the transcription of 
anti-apoptotic genes [108].  It has been shown that NF-κB is constitutively active in 
certain malignancies, promoting tumor cell survival [137, 138]. By using proteasome 
inhibitors, the degradation of IκB by the proteasome is prevented, resulting in the 
inhibition of NF-κB transcriptional activity and induction of tumor cell apoptosis [139, 
140]. However, there are several studies showing that NF-κB activity enhances tumor 
cell sensitivity to apoptosis. NF-κB has been shown to contribute to cell death by 
transcriptional up-regulation of its pro-apoptotic target genes i.e. p53, Bax [141-143]. A 
study on the mouse model of hepatocellular carcinoma (HCC) shows that NF-κB acts 
rather as a tumor suppressor than a tumor promoter [144]. In this case, treatment with 
proteasome inhibitors would perturb NF-κB function as a tumor suppressor.   
 
Bcl-2 family 
A number of members of the Bcl-2 family of anti-apoptotic and pro-apoptotic proteins 
are regulated by proteasomal degradation. The ratio of pro-apoptotic versus anti-
apoptotic Bcl-2 members plays an important role in determination of cellular fate. The 
anti-apoptotic Bcl-2 protein is an integral mitochondrial protein, which upon apoptotic 
stimuli blocks apoptosis and preserves mitochondrial integrity [145]. Reduced levels of 
Bcl-2 protein through proteasomal degradation results in induction of apoptosis by 
release of pro-apoptotic signals [146]. Similarly, pro-apoptotic members of the Bcl-2 
family (Bax, Bak, Bad, Bim, Bik, and Bid) also undergo proteasomal degradation, 
favoring cell survival [147]. It has been demonstrated that Bax is a direct target of the 
proteasome and its degradation is a survival mechanism in human cancer cells. Under 
normal conditions, Bax is localized in the cytosol as a monomer. During apoptosis, Bax 
translocates to mitochondria and undergoes conformational changes to form a functional 
dimer resulting in the loss of mitochondrial membrane potential and release of 
cytochrome c. In turn cytochrome c activates the caspase cascade resulting in cellular 
apoptosis [106]. Increased proteasomal degradation of Bax has been associated with poor 
prognosis in chronic lymphocytic leukemia [148]. Inhibition of proteasomal degradation 
of Bax, in Jurkat T-cell leukemia cells overexpressing Bcl-2, was sufficient to overcome 
protective Bcl-2 effects on apoptosis. Thus, blocking proteasomal degradation may 
enhance the activities of pro-apoptotic proteins rather than those of anti-apoptotic 
proteins [106].  
 
JNK pathway 
The inhibition of the proteasome leads to the induction of apoptosis by activating the 
stress kinase JNK (c-Jun-N-terminal Kinase). JNK belongs to the mitogen-activated 
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protein kinase (MAPK) family. Different mechanisms of JNK induced apoptosis by 
proteasome inhibitors have been proposed. Yang and colleagues show that bortezomib 
induces JNK pathway in non-small cell lung cancer cells probably by induction of p21, 
resulting in growth arrest and apoptosis [149]. In another study, bortezomib-induced 
apoptosis in multiple myeloma cells is associated with translocation of JNK from 
cytosol to mitochondria and release of cytochrome c [150]. 
 
The Role of UPP in protein quality control 
Organisms have evolved protein quality control systems to avoid disruption of cellular 
function by accumulation of abnormal proteins. Heat shock proteins (Hsps) or molecular 
chaperones and UPP are central players in the protein quality control processes. The 
quality control system must be able to distinguish between native (properly folded, and 
assembled) proteins and non-native or abnormal proteins, which include partially 
unfolded, misfolded, or incorrectly modified proteins (i.e. unassembled subunits of 
complexes). Molecular chaperones are induced upon accumulation of non-native 
proteins in the cytosol in an attempt to repair them. Chaperones bind to and stabilize 
exposed hydrophobic residues through ATP-dependent interactions, allowing the protein 
to achieve proper folding. If this fails, the non-native proteins are ubiquitinated and 
targeted for degradation by the 26S proteasome. Thus, the UPP and and molecular 
chaperones are closely connected [151, 152]. Interaction of chaperones and the 
proteasome is not only limited to cytosolic proteins and chaperones, but also rather 
important for the folding of newly synthesized proteins in the endoplasmic reticulum 
(ER) [153].  
 
The quality control in the cytosol and ER 
The close relationship between UPP and molecular chaperones is strengthened by the 
evidence that inhibition of UPP results in up-regulation of Hsps and that Hsps (Hsp70 
and Hsp90) are required for ubiquitination and degradation of some substrates [154, 155]. 
Hsp70 is recruited to the 26S proteasome by binding to a co-chaperone protein Bag-1, 
which contains an UBL domain for the proteasomal binding [156]. Binding of Hsp70 
and Hsp90 to different co-chaperones defines whether a protein becomes repaired or 
degraded by the 26S proteasome. CHIP (C-terminus of Hsp70-Interacting Protein) is 
one of the co-chaperones that is also an ubiquitin E3 ligase. CHIP contains domains 
that interact with both Hsps and ubiquitin conjugating enzymes (E2s), thereby having 
important role in determining the fate of damaged proteins by modulating both the 
chaperone activity and the ubiquitin conjugating activity [157, 158]. Damaged proteins 
are recognized by Hsp70 or Hsp90 and with the help of other co-chaperones they are 
repaired and returned to cellular function. If this fails, CHIP triggers the ubiquitination 
of the damaged protein for the degradation by the 26S proteasome. The activity of 
DUBs is also involved in the decision of repair or degradation. As already mentioned 
above, Ubp6/USP14 and Uch37/UCHL5 rescue substrates from proteasomal 
degradation by removing the ubiquitin from chains attached to damaged proteins, 
thereby allowing the substrate to associate longer with the proteasome, giving a chance 
to molecular chaperones to repair the damage and rescue the protein from degradation 
[151]. Proteasome inhibitors induce the expression of various molecular chaperones or 
heat shock proteins [159]. These are recruited by high molecular weight poly-ubiquitin 
conjugates which are induced upon proteasome inhibition [160].  
The UPP plays an important role in the quality control of newly synthesized proteins. 
After being synthesized, proteins enter the ER in their unfolded state and are then folded 
to reach their functional three dimensional structure [161]. The ER is responsible for 
folding about 7500 different proteins and 30-80% of all newly synthesized proteins end 
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up misfolded, indicating an important role of the UPP to degrade and prevent 
accumulation of non-functionally proteins [162]. Because the UPP is located in the 
cytosol, misfolded proteins have to be transported from ER back to the cytosol for 
degradation (retro-translocation), a process known as ER-associated degradation 
(ERAD) [163]. Transport across ER membrane in both directions is mediated through 
different channels. Proteasomes have also been shown to associate with ER membrane 
through binding of 19S RP base to these channels and a model has been proposed in 
which ATPases of the 19S RP are responsible for extracting proteins from ER through 
the channel for degradation by the proteasome [164]. A proper folding is mediated by 
chaperones residing in the lumen of the ER and the most abundant one is the heat shock 
protein BiP/Grp78 (an ER homologue of Hsp70). Misfolded or unfolded proteins are 
prone to aggregation and BiP/Grp78 is responsible to prevent aggregation of proteins 
bound to it and in this way keep them soluble which is important for proper retro-
translocation through the channels. To promote folding and prevent aggregation of 
proteins BiP/GRP78 uses the energy from ATP hydrolysis within the ER [162, 165].  
Inhibition of the 26S proteasome results in the accumulation of unfolded proteins in the 
ER lumen and induction of ER stress, which in turn elicits the unfolded protein response 
(UPR) [166]. UPR is primarily pro-survival mechanism which functions to increase 
expression of BiP/Grp78 to limit protein aggregation, to increase biosynthesis of 
structural components of the ER and to inhibit protein synthesis in an attempt to reduce 
the load on the ER. If the cyto-protective mechanisms fail, UPR ultimately triggers 
apoptosis [167]. There are three major UPR pathways mediated by the activation of three 
stress sensor proteins: transcription factor-6 (ATF6), inositol-requiring 1α (IRE1α), and 
protein kinase RNA-like ER kinase (PERK). In resting cells, these sensor proteins are 
associated with BiP/Grp78 and are inactive. Induction of ER stress leads to dissociation 
of BiP/Grp78 and activation of the sensor proteins [168, 169]. Upon activation, ATF6 
initiates the transcription of genes encoding ER chaperones to promote protein folding 
and genes promoting ERAD. The second sensor IRE1α activates transcription factor X 
box–binding protein-1 (Xbp1) which is also involved in the activation of genes encoding 
chaperones and ERAD proteins. Activated PERK phosphorylates the translation 
initiation factor-2α subunit (eIF2α) to reduce the rate of protein translation in order to 
decrease the load of misfolded proteins on the ER. Prolonged, intense ER stress is 
cytotoxic. PERK is involved in the induction of apoptosis by activating pro-apoptotic 
transcription factor C/EBP-homologous protein (CHOP) (reviewed by Claudio Hetz) 
[170]. IRE1α also sensitizes cells to apoptosis through activation of c-Jun N-terminal 
kinase (JNK) and an ER resident caspase, caspase 12 in mice or caspase 4 in humans 
[171-173]. The three UPR pathways are often activated together, but selective activation 
of some pathways together with suppression of others can occur [170]. Prolonged UPR 
activation has been shown to induce reactive oxygen species (ROS) and cell death [174].  
 
The role of UPP in response to oxidative stress 
One of the major consequences of aerobic life is the formation of reactive oxygen 
species (ROS) that results in severe damage to DNA, protein, and lipids. In contrast, 
ROS production is beneficial for the destruction of pathogenic micro-organisms [175]. 
ROS constitutes of a variety of partially reduced metabolites of oxygen (e.g., 
superoxide anions, hydrogen peroxide, and hydroxyl radicals) which have higher 
reactivity than molecular oxygen [176]. The main source of ROS are the mitochondria. 
The mitochondrial electron transport chain is the main source of ATP in mammalian cells 
and during energy transduction ROS are generated from electron leakage from the 
respiratory chain. It has been estimated that 1-2% of the total oxygen consumption of 
mitochondria generates ROS [177]. Another source of ROS are the cellular oxidases, 
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e.g. NADPH oxidase [178]. Organisms have developed a series of defense mechanisms 
to fight ROS, which include both enzymatic antioxidant defenses (superoxide 
dismutase, catalase, glutathione peroxidase, thioredoxin reductase) and non-enzymatic 
antioxidants (Vitamin C, Vitamin E and others) [179, 180]. If the cellular antioxidant 
capacity is overwhelmed by ROS, this results in the induction of oxidative stress [181]. 
The outcome of oxidative stress depends on the dose and duration of the exposure to 
ROS, as well as the cell type. Typically, low levels of ROS promote cell proliferation 
while intermediate doses result in growth arrest and senescence. Very severe oxidative 
stress induces cell death via either apoptosis or necrosis. Necrotic cell death is thought 
to result from a higher amount and exposure to ROS than the amount necessary to elicit 
apoptotic cell death [182].  
ROS cause modifications to the amino acids of proteins that generally result in loss of 
protein function and/or enzymatic activity. Oxidized proteins may become misfolded 
leading to aggregate formation [183]. The UPP is responsible for the removal of the 
oxidized proteins [184]. About 70%–80% of turn-over of oxidized protein has been 
attributed to the UPP [185]. Moreover, oxidized proteins can be degraded by the free 
20S CP in an ATP-independent manner and without the presence of ubiquitin [186]. In 
the case of low levels of oxidative stress, the cellular repair mechanisms consisting of 
antioxidants and chaperones can reduce and refold the oxidatively damaged proteins 
and if this fails damaged proteins are either degraded by the proteasomes or they form 
aggregates which are cleared by autophagy [180].  
Paradoxically, ROS can promote normal cellular proliferation and can also induce 
apoptosis in tumor cells. Elevated ROS levels have been implicated in the cell survival 
and tumor progression by the induction of transcription factors NF-κB and activator 
protein 1 (AP1) [187]. On the other hand, enhanced levels of ROS increase p53 
expression and stress kinase JNK pathway that results in the induction of apoptosis 
[188]. Cancer cells have higher levels of ROS than normal cells in order to promote cell 
survival and tumor progression and for this modest levels of ROS are required [189]. 
However, increased ROS levels in cancer cells by using proteasome inhibitors leads to 
apoptosis induction and suppression of tumor growth. Proteasome inhibitors have been 
shown to induce ROS in different cancer cells. In human leukemia cells, the inhibition 
of the proteasome activity resulted in the induction of apoptosis by triggering the pro-
apoptotic stress kinase JNK [190, 191]. Moreover, proteasome inhibitors have been 
shown to induce loss of mitochondrial membrane potential resulting in the induction of 
ROS and apoptosis [192, 193].  
 
Protein aggregation and aggresome pathway  
As mentioned above, some misfolded proteins are beyond salvation by chaperones or 
are not degraded by the 26S proteasome. Instead, these are more prone to aggregation 
through association of the hydrophobic domains with one another. Normally, 
hydrophobic surfaces of proteins are buried in the protein´s interior. Partially folded 
proteins expose hydrophobic domains which are prone to aggregation through 
association with each other. Aggregated proteins show poor solubility in water or 
detergents and by non-native secondary structure. Aggregates are defined by poor 
solubility in water or detergents and by non-native secondary structure [194]. 
Aggregates are sequestered into intracellular foci named inclusion bodies which are 
usually present in low copy numbers, often one per cell. Very quickly after their 
formation, inclusion bodies are transported on microtubules to the microtubule 
organizing center (MTOC) where they are localized to form the aggresome (Figure 4) 
[195]. Most aggresomes are enriched in poly-ubiquitin but there are some exceptions 
like those formed by the expression of misfolded GFP-250 (GFP fused to a 250–amino 
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acid fragment of the cytosolic protein, p115) which do not contain appreciable poly-
ubiquitin [196]. Most aggresomes are pericentrosomal structures of 60-80 nm, 
containing misfolded, aggregated, ubiquitinated proteins. Depolymerization of the 
microtubules with nocodazole prevents formation of the perinuclear aggresomes and 
induces the production of small protein aggregates that are dispersed throughout the 
cytoplasm. Thus, the movement of inclusion bodies requires intact microtubules and 
motor dynein complex is responsible for the transport of inclusion bodies along 
microtubules [183, 195, 197]. Moreover, aggresome formation requires the microtubule-
associated deacetylase HDAC6 which binds both poly-ubiquitinated proteins and dynein 
proteins, through its ubiquitin binding domain (BUZ finger) and a dynein motor binding 
(DMB) domain, respectively, thereby acting to recruit inclusion bodies to dynein motors 
for transport to aggresomes. It has been shown that aggresomes do not form in HDAC6-
deficient cells. Instead, dispersed micro-aggregates are observed throughout the 
cytoplasm [198]. HDAC6 can also modulate aggresome formation through its regulation 
of ubiquitin-dependent protein degradation. HDAC6 binds ubiquitin with high affinity 
which promotes poly-ubiquitin chain stability, leading to the escape of the ubiquitinated 
protein from proteasomal degradation and instead allowing the ubiquitinated substrate to 
accumulate in the aggresomes [199, 200]. The DUB Ataxin-3 has been implicated in 
aggresome formation, although the prices role of the enzyme is still unknown. Ataxin-3 
has been shown to interact with HDAC-6 and dynein motor, raising the possibility that 
Ataxin-3 could serve as an adaptor linking poly-ubiquitinated proteins to the dynein 
motor for the transport to the aggresomes [201].  
In addition to misfolded and aggregated proteins, molecular chaperones and proteasome 
components (19S and 20S proteasome subunits) are recruited to the aggresomes, 
presumably to aid in the clearance of the aggregated proteins [197, 202]. The most 
consistent component of the aggresome is the intermediate filament protein vimentin. It 
forms a cage-like structure wrapped around the aggresome. The function of the vimentin 
cage is unclear but has been proposed to contribute to the stability of the aggresome [183, 
195].  
 
 
 
Figure 4. Aggresome pathway. IF-intermediate filament. MTOC- microtubule organizing center. 
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The association of proteasomes with aggresomes has led to the hypothesis that 
aggresomes might be cleared via the UPP [203]. However, it has been shown that 
aggregated proteins are poor substrates of the proteasome and can actually inhibit 
proteasome activity [204, 205]. Autophagosomes and lysosomes accumulate around the 
periphery of the aggresome, suggesting a role for autophagy in the clearance of 
aggresomes [206]. There are studies showing that aggresome clearance can be 
facilitated by the induction of autophagy. Autophagy is a degradation pathway that 
mediates bulk clearance of cytosolic proteins and organelles by the lysosome. The 
content to be degraded by the autophagy is sequestered in autophagy vesicles with 
double membranes and are called autophagosomes. Autophagosomes subsequently 
fuse to lysosomes where the autophagic contents are released and degraded by 
lysosomal enzymes [206-208]. A protein, p62, is responsible for recruiting aggresomes 
to autophagosomes by binding ubiquitins associated with aggresomes and a component 
of the autophagic membrane LC3, thereby acting as a bridge that connects ubiquitinated 
aggresomes to autophagosomes [209]. The fusion of autophagosomes to lysosomes is 
controlled by HDAC6, which recruits an actin-remodelling machinery responsible for 
the assembly of actin network that stimulates autophagosome–lysosome fusion and 
substrate degradation [210]. Recently, a mechanism for clearance of aggresomes was 
proposed where both the ubiquitin-proteasome and autophagy pathways are involved. 
Hao and colleagues show that aggresomes are first broken into several large fragments 
and then smaller microaggregates, suggesting a “de-aggregation” step that precedes final 
clearance by autophagy. In their model, deubiquitinating enzyme Rpn11/Poh1, plays an 
important role by producing unanchored free ubiquitin chains which bind and activate 
HDAC6.  In turn, HDAC6 induces an actinomyosin system that promotes the de-
aggregation and autophagic clearance of the aggresome [211]. 
The formation of aggresomes followed by proteasome inhibition in cancer cells is 
thought to be cytoprotective. Bortezomib has been shown to induce formation of 
aggresomes in human pancreatic cell lines leading to cytoprotective response to 
proteasome inhibition, probably by shuttling poly-ubiquitinated proteins to lysosomes 
for degradation. Inhibition of aggresome formation with HDAC6 inhibitors or RNAi 
resulted in the sensitization of these cells to bortezomib treatment indicating 
cytoprotective role of aggresomes [212]. Inhibiting both the proteasomal degradation of 
proteins and the aggresome formation results in accumulation of poly-ubiquitinated 
proteins and significant cell stress, followed by the induction of apoptosis [213]. 
Malignant cells use the aggresome pathway as an alternative mechanism for 
ubiquitinated protein degradation and disposal, which can potentially compensate for 
proteasome pathway inhibition and contribute to drug resistance [214]. 
 
 
INHIBITORS OF THE UBIQUITIN PROTEASOME PATHWAY 
 
Selectivity of the proteasome inhibitors 
Protein homeostasis plays an essential role in processes of cancer cell growth, 
development and survival [215]. As described above, the 26S proteasome is crucial for 
the execution of many cellular functions and moreover, increased proteasome activity 
has been associated with malignant disease. Thus, tumorigenic cells are expected to be 
more dependent upon proteasomal activity thereby being more sensitive to its blockade 
[106, 216]. Many types of actively proliferating malignant cells have been shown to be 
more sensitive to proteasome inhibitors than normal cells [217-219]. A concrete 
mechanistic explanation for this selectivity is not yet available but many have suggested 
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that this selectivity is linked to proliferation, deregulation of the cell cycle and induction 
of apoptosis. 
As described earlier, cancer cells use excessive proteasomal degradation to degrade 
proteins that inhibit cell growth e.g. p53, p27 and Bax [105, 106, 220]. Proteasome 
inhibitors elevate the levels of these short-lived proteins and might selectively restore 
apoptosis in these cells [106, 123, 128]. Alternatively, the selectivity of proteasome 
inhibitors for tumor cells has been suggested to depend on the expression of oncogenes, 
such as c-Myc, that deregulate cell proliferation and also induce apoptosis. The induction 
of pro-apoptotic protein Noxa by proteasome inhibitor has been shown to depend on the 
basal levels of c-Myc. Thus, proteasome inhibition selectively induces apoptosis in tumor 
cells compared to normal cells by being dependent on the expression of the oncogene for 
the induction of pro-apoptotic signals [221].  
The cell cycle check point and DNA repair systems are defective in cancer cells and 
when treated with proteasome inhibitors cancer cells are unable to correct the cell cycle 
transition blockade and are driven into apoptosis while normal cells retain checkpoints 
that allow cells to recover from proteasome inhibition. Moreover, one could speculate 
that cancer cells are more vulnerable to proteasome inhibition by being dependent on 
increased protein synthesis to be able to proliferate. These cells might accumulate 
defective proteins at a much higher rate than normal cells, which increases their 
dependency on the proteasome as a disposal mechanism [111]. Indeed, it has been 
reported that B-cell chronic lymphocytic leukemia cells have higher levels of ubiquitin-
conjugated proteins and higher levels of chymotrypsin-like activity compared with 
normal lymphocytes when treated with proteasome inhibitor lactacystin [222]. But the 
picture is more complicated, Guzman and colleagues report that quiescent malignant 
cells are more susceptible to proteasome inhibitors than their proliferating normal 
counterparts [223]. Further understanding of the molecular basis for the selectivity of 
proteasome inhibitors is needed for their development as anticancer agents. 
 
Bortezomib  
Bortezomib (PS-341, Velcade ®; Millennium Pharmaceuticals) is the first proteasome 
inhibitor to gain approval by the US Food and Drug Administration (FDA). The 
approval of bortezomib for the treatment of multiple myeloma and mantle cell 
lymphoma has validated the UPP as a suitable target for the development of novel 
therapies for the treatment of cancer [224, 225].  
Bortezomib is a synthetic dipeptide boronic acid that acts as reversible inhibitor of the 
proteolytic activities of the 20S CP, namely the chymotryptic-like, caspase-like and to 
a lesser extent trypsin-like activities [226-228]. The inhibition of chymotryptic-like and 
caspase-like activities is achieved through interactions of bortezomib with the active N-
terminus threonine of the β5 or β1 subunit, respectively [140]. 
Preclinical studies of bortezomib have demonstrated the ability of this proteasome 
inhibitor to induce growth arrest and apoptosis in a wide range of tumor cell lines and 
animal models of hematologic and solid tumor malignancies [139, 229-231]. Multiple 
mechanisms of bortezomib induced growth arrest and apoptosis have been suggested 
including the inhibition of the NF-κB activation [230], induction of p53 [128], induction 
of CKIs p27 and p21 [232], activation of the stress kinase JNK [149] and induction of 
pro-apoptotic protein Noxa [221]. Many groups have reported the importance of 
bortezomib-mediated inhibition of the pro-survival NF-κB in cancer cells by preventing 
IκB degradation resulting in the induction of cell death [139, 230, 233, 234]. However, 
there are conflicting reports that NF-κB inhibition may not be the key mechanism of 
bortezomib anti-cancer activity and conversely bortezomib treatment may lead to 
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activation of NF-κB [235]. Thus the apoptotic activity of bortezomib may be dependent 
on cell type and the presence of alternative signaling pathways.  
It has been shown that multiple myeloma cells derived from relapsed patients have 
elevated NF-κB levels and that aberrant activation of NF-κB contributes to drug-
resistance [236, 237]. With this in mind, a phase I clinical trial using bortezomib as a 
single agent was conducted on patients with refractory multiple myeloma. One of the 
patients had complete response with improvements in eight other patients observed 
indicated by the reduction of plasma cells in the bone marrow. From this phase I study, 
it was concluded that bortezomib was well tolerated [238]. This study was followed by 
several other phase I, II and III studies where bortezomib was used as a single agent or 
in combination with other conventional anti-cancer drugs like doxorubicin, 
dexamethasone and several others [233, 239]. Furthermore combination studies showed 
that bortezomib could sensitize cancer cells to conventional chemotherapy treatments 
and overcome drug resistance in several hematological malignancies. [229, 240]. 
However; combination strategies on solid tumor types have been less successful, for 
example bortezomib and docetaxel did not show any significant anti-tumor effect in 
hormone refractory prostate cancer [241]. Thus, although bortezomib showed promising 
results in patients with hematologic malignancies, less efficacy was observed in patients 
with solid tumors. 
In addition, the use of bortezomib in clinics has been hampered by the development of 
acquired drug resistance and the occurrence of serious side effects [242]. Many multiple 
myeloma patients that show initial responses later relapse, and a significant sub set of 
patients do not respond to the treatment at all [243]. Moreover, despite being well 
tolerated, bortezomib has been associated with many toxic side effects including 
peripheral neuropathy, low platelet and erythrocyte counts and joint pain, among many 
others [244].  
Resistance to bortezomib can occur either at the level of the proteasome or downstream 
of the enzymatic activity. In different bortezomib-resistant cell lines, mutations or over-
expression of the β5-subunit encoding gene PSMB5 has been shown to contribute to 
resistance [245, 246]. Resistance mechanisms downstream of the proteasome include 
overexpression of molecular chaperones, alterations to regulators of the apoptotic 
machinery, induction of aggresome formation.  
A correlation between loss of sensitivity to bortezomib and up-regulation of the pro-
survival chaperone BiP/Grp78 controlling ER homeostasis has been observed. 
Knockdown of BiP/Grp78 or pretreatment with inhibitors down-regulating BiP/Grp78, 
in cells resistant to bortezomib, has been shown to restore cells sensitivity [247].  
Over-expression of the anti-apoptotic mediator Bcl-2 has been implicated in mediating 
bortezomib resistance. Down-regulation of Bcl-2 with shRNA sensitized Jurkat cells to 
bortezomib treatment, suggesting that endogenous levels of Bcl-2 are sufficient to protect 
against bortezomib treatment. Furthermore, synergistic effects were observed in cells 
treated with an inhibitor of the Bcl-2 protein (ABT-737) and bortezomib [248]. 
Aggresome formation induced by bortezomib has also been reported to be resistance 
mechanism. Ubiquitin conjugates induced by bortezomib treatment are sequestered into 
aggresomes, which is the way of cancer cells to dispose proteotoxic proteins in order to 
promote survival. Disrupting aggresome formation with histone deacetylase inhibitors 
has been shown to overcome bortezomib resistance [212].  
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A new generation of proteasome inhibitors 
The proteasome is an attractive target for cancer therapy and there is a need for new 
proteasome inhibitors which will overcome drug-resistance and have lower toxic side 
effects to be able to improve the outcome of patients. 
A new generation of proteasome inhibitors with irreversible modes of action and which 
are orally bioavailable is currently being evaluated. These new proteasome inhibitors are 
being developed with the aims of reducing toxicity, overcoming bortezomib resistance, 
enhancing anti-tumor activity and improving effectiveness of proteasome inhibition. 
Carfilzomib a peptide-epoxyketone that irreversibly inhibits the chymotrypsin-like 
activity of the proteasome has recently been approved by the FDA for the treatment of 
multiple myeloma patients who have received at least two prior therapies. A major 
advantage of using carfilzomib as a therapeutic agent is its ability to overcome 
bortezomib resistance. Similarly to bortezomib, carfilzomib is, administered 
intravenously. However, several orally bioavailable proteasome inhibitors are currently 
in clinical trials [249, 250].  
Marizomib is an orally available irreversible proteasome inhibitor that inhibits all three 
(chymotrypsin-like, caspase-like and trypsin-like) activities of the 20S CP [251, 252]. 
The advantage of inhibiting all three activities is thought to be due to a more extensive 
inhibition of proteasome, thereby inducing pro-apoptotic pathways to a greater extent 
than inhibiting the chymotrypsin-like activity alone [253]. Marizomib shows clinical 
activity on bortezomib-refractory multiple myeloma patients and is well tolerated with 
no peripheral neuropathy side effects [252]. In conclusion, the new generation of 
proteasome inhibitors are creating opportunities to overcome resistance and enhance 
clinical outcomes. However, one of the biggest challenges that has yet to be overcome is 
to identify proteasome inhibitors that have better effects on advanced solid tumors. 
Targeting other components of ubiquitin proteasome pathway is an intriguing possibility 
and it has been suggested that targeting the UPP upstream of the 20S CP may lead to 
improved therapy options for cancer patients [254].  
 
Targeting deubiquitinating enzymes  
As mentioned above, 98 DUBs have been identified in the human genome and recent 
evidence suggests that many of these are overexpressed or show altered activity in tumor 
cells [255]. Therefore, finding inhibitors that target DUB activity may therapeutically be 
beneficial. Several pan-DUB inhibitors, which target both proteasomal and non-
proteasomal DUBs have recently been described. 
The C-terminally modified vinyl sulfone derivative of ubiquitin, UbVS, is an irreversible 
DUB inhibitor that is used as an active site directed probe to detect enzymatically active 
DUBs [53]. Ubiquitin aldehyde (Ubal) is reversible inhibitor of ubiquitin C-terminal 
hydrolases (UCHs) and ubiquitin specific proteases (USPs) that prevents the hydrolysis 
of poly-ubiquitin chains on substrate proteins in vitro [256]. Due to their high molecular 
mass and lack of specificity these inhibitors have not been considered as therapeutic 
agents and instead are primarily used as research tools. However, as research tools they 
may be fundamental in aiding the design and identification of small molecule DUB 
inhibitors to be used as therapeutic agents.  
WP1130 (degrasyn) is a small-molecule compound that inhibits several DUBs, both 
proteasomal and non-proteasomal, including USP9X, USP5, USP14 and UCHL5. In 
cells, WP1130 inhibition of DUB activity resulted in the accumulation of poly-
ubiquitinated conjugates, down regulation of anti-apoptotic mediators such as MCL-1 
and up-regulation of pro-apoptotic proteins, such as p53 [257]. Furthermore, Pham and 
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colleagues showed that WP1130 in combination with bortezomib had antitumor activity 
in lymphoma animal model [258]. 
A more specific small molecule inhibitor of DUB activity is IU1. IU1 is a reversible 
inhibitor of USP14 and binds specifically to the proteasomal-associated form of USP14 
inhibiting its DUB activity. IU1 has been shown to enhance the degradation of 
proteasome substrates and has been suggested as a treatment option for 
neurodegenerative diseases that are associated with the accumulation of misfolded and 
aggregated proteins. Due to its capacity to increase proteasome activity this inhibitor may 
not be a suitable therapeutic agent for cancer treatment [78].  
Recently, a curcumin analog (AC17) has been shown to irreversibly inhibit the 
deubiquitinase activity of the 19S RP. AC17 was shown to inhibit NF-κB activity and to 
reactivate p53 in human lung cancer cells and was also shown to have anti-tumor activity 
in an in vivo model of human lung cancer. This anti-tumor activity was associated with 
proteasome inhibition, NF-κB blockade and p53 reactivation. However, it is still unclear 
which deubiquitinating enzymes are inhibited with AC17 [259].  
Although many DUB inhibitors have been identified and characterized in recent years, 
their broad range of activity limits their clinical use, thus the identification of inhibitors 
with more specific targets is required.  
 22 
AIMS OF THESIS 
 
The general aim of the thesis was to investigate the potential of a deubiquitinase inhibitor, 
b-AP15, as a therapeutic agent for cancer treatment.    
 
The specific aims of these studies were; 
 
 Paper I: To elucidate the mechanism of action of b-AP15. 
 
 Paper II: To characterize the response of tumor cells to b-AP15 and to compare 
this response to the elicited by the clinically used proteasome inhibitor 
bortezomib.  
 
 Paper III: To examine cellular uptake and metabolism of b-AP15 and to 
examine reversibility of target binding and commitment to cell death. 
 
  Paper IV: To examine the faith of misfolded proteins accumulating in b-AP15-
exposed cells. 
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RESULTS & DISCUSSION 
 
PAPER I 
Inhibition of proteasome deubiquitinating activity as a new cancer therapy. 
 
A screen conducted to identify compounds that induce p53 independent apoptosis led to 
identification of a number of compounds, one of which was NSC687852 (b-AP15). This 
compound was later identified in a screen of compound inducing the lysosomal apoptosis 
pathway [260, 261]. In this study we show that b-AP15 is a potent proteasome inhibitor 
that functions via a novel mechanism, namely the inhibition of two of the 19S RP 
associated deubiquitinating enzyme, UCHL5 and USP14.  
 
Firstly we sought out to elucidate the effect of b-AP15 on the cellular proteasome 
function. We used a reporter cell line expressing a proteasome targeted fluorescent 
substrate: ubiquitin tagged yellow fluorescent protein (UbG76V-YFP). Upon proteasome 
inhibition, the UbG76V-YFP reporter protein accumulated in cells, indicating impaired 
proteasome degradation. b-AP15 induced a dose-dependent accumulation of the 
UbG76V-YFP. Proteasome inhibition is associated with the induction of poly-ubiquitin 
conjugates, which were indeed observed in b-AP15 treated cells. Importantly, 
compared to the proteasome inhibitor, bortezomib, b-AP15 induced poly-ubiquitin 
conjugates of a higher molecular weight, indicating different mechanism of action.  
 
Many proteasome inhibitors inhibit the proteolytic activities of the 20S CP. Thus, we 
next investigated if b-AP15 inhibited this activity by using fluorogenic substrates for 
chymotrypsin-like, caspase-like and trypsin-like activities, respectively. b-AP15 was 
unable to perturb these activities, thus we hypothesized that b-AP15 might act upstream 
of the 20S CP. Chemical structure of b-AP15 contains an α-β dienone with two 
sterically accessible β carbons. A similar pharmacophore has been described in a 
variety of deubiquitinase inhibitors, thus we hypothesized that b-AP15 may inhibit 
DUB activity [262]. Firstly, we showed using a combination of tagged DUB active site 
probes (HA-UbVS) and the flurogenic DUB substrate (Ub-AMC)  that b-AP15 was not 
a general inhibitor of total deubiquitinase activity in cells. To further investigate the 
inhibitory effects of b-AP15 on DUB activity we used biochemical assays with purified 
19S RP and 26S proteasomes on different proteasome substrates and K48- and K63-
linked ubiquitin tetramer chains. b-AP15 inhibited deubiquitination of the proteasome 
substrates and disassembly of K48 and K63 chains, indicating the possibility of b-AP15 
being a proteasomal DUB inhibitor. Three DUBs are linked to the proteasome POH1, 
UCHL5 and USP14. UCHL5 and USP14 are cysteine proteases, while POH1 is a 
metalloprotease. We ruled out the possibility that b-AP15 inhibited POH1 by using a 
general cysteine protease inhibitor for cysteine DUBs (UCHL5 and USP14) and a metal 
chelator for the metalloprotease POH1. After co-treating purified 19S regulatory 
particles with b-AP15 and cysteine protease inhibitor some deubiquitinase activity was 
still observed while co-treatment with b-AP15 and metal chelator resulted in abolished 
DUB activity, suggesting that b-AP15 inhibited one or both of the cysteine proteases. 
The hypothesis was further supported by using hemagglutinin-tagged ubiquitin 
vinylsulphonone (HA-UbVS) as a probe, which is utilized for detecting active DUBs. 
Treatment with b-AP15 in biochemical assays and in cells resulted in a loss of Ub-VS 
labeling of two DUBs with molecular weights corresponding to UCHL5 and USP14. 
From these experiments we concluded that b-AP15 inhibited the activities of the 
cysteine proteases UCHL5 and USP14.  
 24 
 
In cells, b-AP15 induced cell cycle arrest and apoptosis when used at concentrations 
required for the accumulation of poly-ubiquitin conjugates. Moreover, decreased cell 
viability was observed at similar concentrations thereby coupling proteasome 
inhibition to the cytotoxic effects of the drug. Importantly, b-AP15 induced apoptosis 
was insensitive to disruption of p53 or Bcl-2 overexpression. We further investigated 
the selectivity of b-AP15 and showed that it was more toxic to colon carcinoma cells 
than to immortalized epithelial cells or peripheral blood mononuclear cells. Notably, 
differences observed with b-AP15 were larger compared to bortezomib, indicating that 
b-AP15 might have a larger therapeutic window compared to bortezomib.  
 
Next we evaluated the anti-tumor activity of b-AP15 in different animal models 
representing both solid tumors and hematological malignancies. Daily administration 
of b-AP15 to mice with FaDu squamous carcinoma xenografts resulted in significant 
antitumor activity and induction of caspase cleaved keratin 18 in mouse plasma, an 
indicator of drug-induced apoptosis in human tumor xenografts [263]. Bcl-2 
overexpression has been reported to mediate resistance to proteasome inhibitors [248]. 
So we examined disease-free survival in mice with HCT-116 colon carcinoma 
xenografts overexpressing Bcl-2. The onset of tumor growth was delayed in the treated 
group with two out of six mice disease free at the termination of the study, suggesting 
that b-AP15 may be used to overcome Bcl-2-mediated drug resistance in tumors.  
In previous models b-AP15 was administered daily so we investigated the anti-tumor 
effect of b-AP15 using a less frequent schedule. Treatment with b-AP15 every fourth 
day significantly reduced tumor growth in mice with orthotopic breast carcinoma with 
decreased numbers of pulmonary metastases detected in b-AP15 treated mice. We also 
observed increased accumulation of K48-linked poly-ubiquitin chains and activated 
caspase 3 in tumor section staining, coupling anti-tumor activity of b-AP15 in vivo to 
the inhibition of proteasome function.   
Lastly, the effect of b-AP15 on tumor cell invasion was investigated in an acute 
myeloid leukemia model. Eight out of ten b-AP15 treated mice had regressed leukemia. 
Animals in the control group had massive invasion of myeloid leukemic cells into the 
liver tissue and invasion of leukemic blasts in the ovary tissue which was absent in 
biopsies from the b-AP15 treated groups.  
  
In conclusion, we identified b-AP15 as a novel proteasome inhibitor that functions by 
inhibiting the DUB activity of the 19S RP and which displays anti-tumor activity both 
in vitro and in vivo. 
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PAPER II 
Induction of tumor cell apoptosis by a proteasome deubiquitinase inhibitor is 
associated with oxidative stress. 
 
Proteasome inhibition leads to the induction of a wide range of cellular responses. In this 
study we try to delineate the different cellular responses induced by b-AP15 compared 
to the conventional proteasome inhibitor bortezomib. 
 
To identify which molecular pathways were affected by b-AP15 treatment, we performed 
transcriptional profiling on 84 genes whose expression is known to be altered by 
chemotherapeutical reagents, including proteasome inhibitors. Analysis of the gene 
expression profiles showed that both b-AP15 and bortezomib induced the up-regulation 
of a common subset of genes involved in oxidative stress, ER stress, heat shock and 
the immediate early response. Notably, the HSPA6 gene which encodes 
HSP70B´protein was induced >1000 fold following b-AP15 treatment compared to 60 
fold induction by bortezomib. Hsp70B´has been shown to be induced by proteasome 
inhibitors and is induced under conditions of severe proteotoxic stress [264]. One 
reason for this disparity could be the accumulation of higher molecular weight ubiquitin 
conjugates as a consequence of UCHL5 and USP14 inhibition observed in b-AP15 
treated cells compared to bortezomib. Moreover, the induction of genes associated with 
oxidative stress (HMOX-1, PHOX/p67) and immediate early response (JUN, GADD34, 
GADD45A, and GADD45B) were overall strongly induced by b-AP15 compared to 
bortezomib. Lastly, the expression of genes associated with ER stress were similarly 
induced by both drugs.  
 
Both b-AP15 and bortezomib activated caspase-4, an ER resident caspase that is 
activated upon ER stress induction [172]. The role of ER stress in b-AP15- and 
bortezomib-induced apoptosis was assessed by chemical inhibitors or siRNA against 
caspase-4, either of which resulted in the inhibition of apoptosis induced by both drugs. 
The data suggest contribution of ER stress in induced apoptosis. In contrast to 
bortezomib, b-AP15 induced phosphorylation of eIF2α in several different cell lines. 
Activated eIF2α has been suggested to reduce the load of misfolded proteins on the ER 
promoting cell survival [265]. Bortezomib has been shown previously to inhibit ER 
kinase (PERK) leading to the inhibition of phosphorylation of eIF2α and has been 
proposed to be important for the induction of apoptosis by this agent [266]. Despite the 
phosphorylation of eIF2α, b-AP15 induced a more rapid apoptosis compared to 
bortezomib, evident from our studies on the kinetics of apoptosis induction. Thus, 
suggesting that translational suppression might not be important for the induction of 
apoptosis by agents that impair proteasome function.  
 
We further investigated the role of ROS production in b-AP15 induced apoptosis. To 
assess the levels of ROS production by b-AP15 and bortezomib we utilized fluorescent 
ROS probe 2′, 7′-dichlorofluorescin diacetate (DCFH-DA) and determined that both 
drugs induced ROS production, although levels of ROS were higher in b-AP15 treated 
cells. Consistent with these results the expression of HMOX-1 protein, which is 
considered to be one of the most sensitive and reliable indicators of cellular oxidative 
stress [267], was higher following b-AP15 treatment. Others have reported the 
important role of ROS production in mediating bortezomib-apoptosis, so we sought to 
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investigate if the ROS production generated by b-AP15 was involved in the induction 
of apoptosis. Using different anti-oxidants to scavenge ROS resulted in inhibition of 
apoptosis by both b-AP15 and bortezomib, confirming previous findings. The role of 
ROS in apoptotic signaling induced by bortezomib and other proteasome inhibitors has 
been controversial, due to ability of anti-oxidants, such as NAC and Vitamin C, to form 
complexes with these drugs [268, 269]. Anti-oxidants used in this study did not interact 
with b-AP15, suggesting that b-AP15 induced apoptosis could indeed be mediated by 
oxidative stress.  
Prolonged oxidative stress has been reported to inactivate the proteasome function, which 
raised a question if b-AP15 induced ROS production contributed to the same 
phenomenon. To investigate this further we utilized a reporter cell line expressing a 
proteasome targeted fluorogenic substrate, UbG76V-YFP. Treatment of these cells with 
b-AP15 in the presence of a scavenger during drug treatment did not affect the 
accumulation of the UbG76V-YFP signal, indicating that the inhibition of the proteasome 
function was due to the direct action of b-AP15 and not due to increased ROS levels. 
Additional experiments with different b-AP15 analogues confirmed that proteasomal 
blocking was associated with induction of oxidative stress. b-AP15 analogues that 
generated poly-ubiquitin conjugates similarly to b-AP15 also induced high levels of 
HMOX-1 protein, whereas analogues that failed to induce poly-ubiquitin conjugates 
were unable to induce HMOX-1 expression. Furthermore, we show that stress kinase 
JNK is activated upon b-AP15 treatment and is involved in the induction of apoptosis by 
b-AP15. The activation of JNK was further shown to be mediated by b-AP15 induced 
oxidative stress.  
 
In this paper we conclude that b-AP15 is a more potent inducer of apoptosis compared 
to bortezomib and that oxidative stress is a key mediator of the strong pro-apoptotic 
potential of b-AP15.  
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PAPER III 
The 19S deubiquitinase inhibitor b-AP15 is enriched in cells and elicits rapid 
commitment to cell death. 
 
In this study we address several questions with regard to the mechanism of action and 
pharmacology of the deubiquitinase inhibitor b-AP15. 
  
As already mentioned in papper I, b-AP15 contains a pharmacophore with an α-β 
dienone with two sterically accessible β carbons that has been described to inhibit 
deubiquitinase activity. The α, β-unsaturated dienone serve as a Michael acceptor that 
interacts with thiol groups of cysteines in deubiquitinating enzymes. b-AP15 also 
contains another Michael acceptor (an acrylamide residue) that potentially could be 
reactive. We sought out to investigate which of these Michael acceptors mediated the 
biological activity of b-AP15. New compounds were synthesized in which the 
acrylamide residue and the α, β-unsaturated carbonyls were substituted. Compared to b-
AP15, compounds with the substituted acrylamide induced cell death to a similar degree 
as b-AP15. In contrast, substitution of the unsaturated carbonyls lead to reduced 
cytotoxic effects. Thus, the biological activity of b-AP15 is governed primarily by the 
reactivity of α, β-unsaturated carbonyl pharmacophore. 
 
A DUB inhibitor, AC17, with similar chemical properties to b-AP15 have been reported 
to be irreversible inhibitor [259]. However, in paper I we report that b-AP15 is reversible 
inhibitor. The reversibility of b-AP15 was further investigated in this study. We used Ub-
VS to detect active proteasomal USP14. Dilutions of b-AP15 treatment of cell extracts 
lead to reappearance of the active USP14, indicating b-AP15 to be a reversible inhibitor 
of deubiquitinase activity. We also investigated if the inhibition of proteasome function 
and induction of apoptosis by b-AP15 was reversible in cell lines. We utilized a reporter 
cell line expressing a proteasome targeted fluorescent substrate, ubiquitin tagged yellow 
fluorescent protein (UbG76V-YFP). Treatment of cells with low b-AP15 concentrations 
for one hour resulted in the induction of poly-ubiquitin conjugates, which started to 
decline four hours after drug removal. Similar pattern was observed for the reporter 
protein UbG76V-YFP and proteasome substrate p21Cip1, indicating that b-AP15 was 
reversible inhibitor of the proteasome function. However, the cleavage of caspase 3 
and PARP was observed twenty four hours after wash-out, suggesting that despite 
reversible inhibition of the proteasome function cells still committed to apoptosis after 
one hour of b-AP15 exposure.  
 
In study I, we also observed that higher concentrations of b-AP15 were required to inhibit 
deubiquitinase activity in biochemical assays than in assays of proteasomal function on 
cells. The reason for this difference was further investigated in this study. When using 
Ub-AMC as a substrate for DUBs, an IC50 ~ 17µM of b-AP15 was observed while 1µM 
of b-AP15 was sufficient to inhibit the activity of USP14 in colon carcinoma cells.  We 
hypothesized that the reason for this discrepancy could be due to effective uptake of b-
AP15 from the medium and enrichment of this compound in cells, which also could 
explain the fast commitment of cells to apoptosis.   Distribution from medium to cells 
was examined by the incubation of b-AP15 in the presence or the absence of cells. Only 
one hour of incubation with b-AP15 resulted in strong uptake of the drug by cells from 
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the medium. Using radiolabeled b-AP15 we observed rapid uptake of the drug into cells 
after thirty minutes incubation. Drug washout resulted in a ~40% decrease of 
radiolabeled b-AP15 over two hours with a ~50% decrease observed up to ten hours. 
These results lead us to the assumption that a sufficient amount of drug is available for 
proteasome inhibition even after washout, when using high drug concentrations. 
Consistent with our hypothesis, treatment of reporter UbG76V-YFP expressing cells with 
higher b-AP15 concentrations resulted in the accumulation of poly-ubiquitin 
conjugates that were still abundant eight hours after drug removal. Moreover, we 
observed low concentrations of free intracellular b-AP15, suggesting that majority of the 
drug molecules may bind to cellular macromolecules. As described earlier Michel 
acceptors react with thiol groups in cysteines of proteins, suggesting that b-AP15 was 
binding to intracellular thiols. Pretreatment of cells with N-ethylmaleimide, a covalent 
inhibitor of DUB activity and a Michael acceptor, prior the treatment of cells with 
radiolabeled b-AP15 resulted in the inhibition of the cellular uptake of b-AP15, 
indicating that the uptake of b-AP15 was via a thiol-dependent mechanism. 
 
Since it is unlikely that b-AP15 binds solely to the thiols present in the proteasomal 
deubiquitinases, we also report an off-target activity of b-AP15, namely irreversible 
inhibition of thioredoxin reductase. The thioredoxin enzymatic system is important for 
redox regulation of cellular function. We investigated the importance of the thioredoxin 
reductase inhibition by b-AP15 on the cellular response. The inhibition of thioredoxin 
reductase on its own could not explain the strong induction of oxidative stress and 
apoptotic activity of b-AP15 observed in paper II, suggesting that it is of limited 
importance for b-AP15-mediated cytotoxicity. Another important enzymatic system in 
regulating cellular redox-homeostasis is the glutathione system. In contrast to 
thioredoxin, glutathione reductase was not inhibited by b-AP15, possibly because of the 
selectivity of b-AP15 for some cellular cysteines present in thioredoxin reductase but not 
in glutathione reductase.  
 
From this study we conclude that b-AP15 is a reversible inhibitor of deubiquitinating 
activity and proteasome function. Although b-AP15 is reversible inhibitor, cells treated 
with b-AP15 rapidly become committed to cell death within one hour of drug treatment. 
This commitment to cell death may be explained by the rapid uptake and enrichment 
in cells and by the harmfulness of misfolded proteins not deposited in aggresomes (see 
paper IV). These findings are encouraging for the development of b-AP15 for clinical 
use.  
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PAPER IV 
Inhibitor of proteasome deubiquitinase activity inhibits cytoprotective-aggresome 
formation in cancer cells.    
 
Blockade of the proteasome results in the accumulation of poly-ubiquitinated conjugates 
that are prone to aggregation. Such aggregates are sequestered at the peri-nuclear region 
in complexes termed aggresomes. Bortezomib has been shown to induce the aggresome 
pathway, which may be used by malignant cells as an alternative mechanism for 
sequestering and degrading poly-ubiquitinated proteins, potentially resulting in drug 
resistance [212-214]. In this study, we investigate if blocking the deubiquitinating 
activity of the proteasome by b-AP15 is involved in the induction of aggresome pathway.  
 
The p62 protein is an ubiquitin-binding scaffold protein that has been shown to co-
localize with ubiquitinated protein aggregates and is a key mediator of aggresome 
formation [209]. Treatment of cells with either b-AP15 or bortezomib for shorter time 
points resulted in the formation of dispersed aggregates throughout the cytosol, evident 
from the co-localization of p62 and K48-polyubiquitin in the formed aggregates. Longer 
exposure to bortezomib, resulted in the formation of a single juxta-nuclear poly-ubiquitin 
aggregate that co-localized with p62 in >60% of the cells when treated with bortezomib. 
In contrast, prolonged b-AP15 treatment resulted in the formation of multiple K48-
ubiquitin/p62 positive aggregates in cytoplasmic and peri-nuclear regions that were not 
characteristic aggresome structures.  
 
Aggresome formation is accompanied by redistribution of the intermediate filament 
protein vimentin, which forms a cage surrounding the nascent aggresome at the peri-
nuclear region [183, 195, 196]. These observations made us investigate the vimentin 
localization in cells treated with b-AP15 and bortezomib. Both drugs induced vimentin 
re-localization, evident from the appearance of condensed vimentin localized at the peri-
nuclear region. In agreement with previous results, bortezomib treated cells displayed 
vimentin cage structures surrounding the aggresome, which were absent in b-AP15 
treated cells. Results so far suggest that poly-ubiquitinated conjugates induced by b-
AP15 form aggregates but are incapable of forming aggresome structures.   
 
Transport of aggregates along microtubules to MTOC is required for aggresome 
formation. It has been shown that depolymerization of microtubules with microtubule 
inhibitors prevents the formation of peri-nuclear aggresomes, resulting in the 
production of aggregates dispersed throughout the cytoplasm.  [183]. The observation 
that treatment with b-AP15 also generated multiple aggregates in the absence of typical 
aggresome formation, made us wonder whether b-AP15 disrupted components of the 
aggresomal pathway. When we co-treated cells with b-AP15 and bortezomib a lower 
number of aggresomes was observed compared to bortezomib treatment, suggesting 
that b-AP15 partially inhibited aggresome formation. To further investigate this we 
utilized a GFP chimera GFP250 that readily forms peri-nuclear aggresomes that are 
dependent on the tubulin network but independent of the ubiquitin-proteasome system 
[196]. Treatment with both bortezomib and b-AP15 further enhanced the formation of 
aggresomes implying that b-AP15 inhibits aggresome formation in a microtubule-
independent, but ubiquitin-dependent, manner.  
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We sought to investigate if b-AP15 interfered with another crucial component of the 
aggresomal pathway, the deacetylase HDAC6. HDAC6 is responsible for recruiting 
aggregates, through its ubiquitin binding domain, for the transport to aggresomes [198]. 
HDAC6 is known to be ubiquitinated and has also been shown to associate with DUB 
activity [199]. We hypothesize that b-AP15 might interfere with the ubiquitination 
profile of HDAC6 resulting in non-functional HDAC6 for aggresome formation. To 
investigate this we transfected cells with His-tagged ubiquitin and HDAC6. We observed 
increased levels of poly-ubiquitinated HDAC6 in b-AP15 treated cells (6-fold induction) 
compared to bortezomib treated cells. This difference may be due to inhibition of DUBs 
by b-AP15 involved in the regulation of HDAC6.  
 
Our results show that b-AP15 blocks aggresome formation in an ubiquitin-dependent 
manner evident from our experiments with co-treatment with b-AP15 and bortezomib 
and also our experiments with GFP-250 chimera. We hypothesize that b-AP15 may 
inhibit HDAC6 mediate aggresome formation but whether this depends on the poly-
ubiquitination of HDAC6 by b-AP15 or some other mechanism needs further 
investigation. Since it has been shown that HDAC6 inhibitors effectively synergized 
with bortezomib leading to disrupted aggresome formation and induced cytotoxicity, 
experiments using RNAi or pharmacological inhibitors to block HDAC6 would be 
informative for future studies [213]. Also we have not directly shown that the 
disruption of aggresomes by b-AP15 is due to inhibition of UCHL5 and USP14, which 
needs further investigation.  
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CONCLUSIONS & FUTURE PERSPECTIVES 
 
The thesis identifies a novel small molecule inhibitor of the proteasome, b-AP15. b-AP15 
blocks proteasome function by the inhibition of deubiquitinating enzymes, UCHL5 and 
USP14. For the future development of b-AP15 it is important to understand the exact 
specificity of b-AP15 to UCHL5 and USP14, given the notion that these two DUBs 
belong to different families of this class of enzymes. So far, we can only speculate that 
b-AP15 inhibition of UCHL5 and USP14 could be related to the unique confirmations 
of these enzymes or could be because of drug-induced alterations of the structure of the 
19S RP.  
 
We also show that b-AP15 elicits anti-tumor effects in a number of tumor models 
representing both hematological and solid tumor malignancies. The anti-tumor activity 
of b-AP15 both in vitro and in vivo is correlated to the inhibition of proteasome function.  
The potent induction of apoptosis by b-AP15 was associated with strong induction of 
oxidative stress. However, in an attempt to rescue cells from b-AP15 induced 
cytotoxicity by scavenging ROS we observed no change in the overall cell survival, 
suggesting that there are other mechanisms that will eventually cause cell death. In 
contrast to b-AP15, scavenging bortezomib-mediated ROS production resulted in 
increased cell survival. We propose a model for the potent anti-tumor activity of b-AP15 
(Figure 5). Inhibition of deubiquitinating activity of the proteasome by b-AP15 results in 
the accumulation of higher molecular weight ubiquitin-substrate complexes compared to 
the induction of these complexes by bortezomib targeting the 20S enzymatic activities, 
resulting in the stronger proteotoxicity by b-AP15. The high molecular weight ubiquitin 
conjugates induced by b-AP15 are either sequestered into aggregates or they associate 
with membranes of different organelles via the exposed hydrophobic patches on the 
surface of protein substrates causing organelle dysfunction (depolarization and structural 
collapse) and eventually cell death.   
 
Overexpression of Bcl-2 is involved in bortezomib-mediated resistance. In contrast, b-
AP15 is insensitive to the overexpression of Bcl-2 suggesting that b-AP15 could be used 
as a second line therapy in patients to overcome bortezomib resistance. Indeed, a study 
on b-AP15 and multiple myeloma has recently been published, in collaboration with our 
group, where it is shown that b-AP15 significantly decreased cell viability of multiple 
myeloma cells derived from patient who have relapsed from prior therapies with 
bortezomib [270].  
 
Furthermore, b-AP15 is not a genotoxic agent. The use of DNA-damaging agents in 
clinics has been limited by the adverse side effects and increased risk of secondary 
cancers as a consequences of agents' genotoxicity.   
 
The findings in this thesis provide a basis for evaluation of b-AP15 as a potential therapy 
for cancer treatment.  
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Figure 5.  The effect of b-AP15 treatment on cancer cells. 
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